Wittington Investments has agreed to acquire Boots from Sycamore Partners and Stefano Pessina in a US$8.9bn transaction. The deal passes the UK health and beauty chain, including its No7 Beauty own-brand line, to the Weston family — the Canadian dynasty behind Loblaw, Shoppers Drug Mart and a controlling stake in Primark owner Associated British Foods.

The agreement covers Boots' UK and Ireland operations, No7 Beauty, Boots Opticians, the Boots Thailand business and the group's franchised operations. Closing targets the first quarter of 2027, pending regulatory approval. Galen Weston, Chairman of Wittington Investments, takes the Chair at Boots once the transaction completes.

What does the acquisition change for cosmetics manufacturers and suppliers?

The cosmetics industry will watch how No7 — historically Boots' flagship skincare and colour cosmetics label — slots into a portfolio already anchored in mass-market health, wellness and pharmacy retail. Suppliers with listings inside Boots' own-brand lines should expect continuity of stocking under new ownership. Category review cycles are likely once integration begins, typically visible in spring trading updates.

Alex Baldock, who continues as Boots CEO, framed the move as acceleration rather than disruption. "For all of our social impact and commercial success to date, the opportunity ahead is even greater," Baldock said. "I look forward to making the most of that opportunity and building a world-class Boots for our colleagues, customers, patients, and communities."

Galen Weston pointed to capital reinvestment rather than cost-cutting as the operating thesis. "Boots is one of Britain's most enduring businesses, with a rich heritage, a trusted name and a vital role in everyday life across the UK and Ireland," Weston said. "We see a meaningful opportunity to make a great business even better through stable long-term ownership, further capital investment, and the renewed operating focus required to serve customers with excellence for generations to come."

Will private family ownership shift Boots' beauty strategy?

Wittington's track record at Primark centres on vertically integrated sourcing, tightly controlled pricing and limited external advertising. Applied to Boots, that philosophy could favour deeper in-house development around No7 and other Boots-owned labels, while slowing expansion of third-party premium fragrance or dermatological brands that currently drive higher-margin growth.

The Weston family previously held UK luxury department store Selfridges and sold it in 2022 — a rotation outside the group's grocery and pharmacy core. That precedent should temper expectations of a deep pivot into prestige beauty at Boots. Watch the buyer's first annual merchandising review after close, the moment stable long-term ownership promises meet shelf-space reality.

Who now controls the rest of the former WBA footprint?

Pessina and his family will retain Farmacias Benavides in Mexico and Alliance Healthcare Deutschland after divesting Boots itself. Sycamore Partners and Pessina had separated the UK retailer from Walgreens Boots Alliance last year before the new deal. The carve-out keeps Boots' UK pharmacy footprint and own-brand portfolio inside Wittington's perimeter, while European wholesale and Latin American pharmacy assets stay with the Pessina family.

What timelines and filings should suppliers track?

Three dates now matter:

• Regulatory clearance, expected to focus on UK pharmacy market concentration rather than beauty retail concentration
• The Q1 2027 closing target
• The first post-completion category plan from Boots' buying team

For formulators, brand owners and packaging suppliers with current listings inside Boots or No7, the next material signal arrives when Baldock's team publishes its first spring trading update under Wittington — and again when the new buyer's first merchandising review follows close. Until then, order books, forecast commitments and listing terms remain valid under existing purchasing arrangements.